Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01 HG008773, T32HG010464, R01 HG008773)
Received: 20 March 2019
Accepted: 31 March 2020
First Online: 18 May 2020
: G.R.A. is an employee of Regeneron Pharmaceuticals. He owns stock and stock options for Regeneron Pharmaceuticals. B.M.N. is a member of the Deep Genomics Scientific Advisory Board, has received travel expenses from Illumina and also serves as a consultant for Avanir and Trigeminal solutions.